Table 1 Descriptive covariates, showing clinicopathological, treatment and lifestyle features of patients from which the samples were taken as well as the results that were obtained for biomarker measurement

From: Cadherin-5: a biomarker for metastatic breast cancer with optimum efficacy in oestrogen receptor-positive breast cancers with vascular invasion

		NSR (n=60)		REC (n=52)		Total subjects (n=112)
		Mean (s.d.)	Range	Mean (s.d.)	Range	Mean (s.d.)	Range
Age at diagnosis	*	52.19 (9.29)	33.45–71.76	53.21 (11.51)	31.80–74.50	52.66 (10.29)	31.80–74.50
Tumour size (mm)	*	24.14 (15.53)	2–70	28.54 (20.51)	5–110	26.15 (18.02)	2–110
Height (m)		1.63 (0.06)	1.50–1.79	1.63 (0.07)	1.47–1.80	1.63 (0.06)	1.47–1.80
Weight at diagnosis (kg)		72.41 (13.60)	51.5–114.0	69.64 (14.20)	47.7–127.0	71.12 (13.60)	47.7–127.0
BMI at diagnosis		27.31 (4.81)	17.61–39.02	26.14 (5.02)	17.95–43.84	26.76 (4.92)	17.61–43.84
CDH5 (ng ml⁻¹)		9.51 (9.84)	0.12–43.03	13.77 (13.93)	0.03–79.10	11.49 (12.05)	0.03–79.10
HPA (AU ml⁻¹)		151.98 (143.56)	3.22–611.27	144.64 (137.34)	11.26–839.78	148.58 (140.11)	3.22–839.78
CDH5/HPA ratio (ng AU⁻¹)		0.085 (0.067)	0.003–0.296	0.114 (0.083)	0.001–0.586	0.098 (0.076)	0.001–0.586
		n	%	n	%	n	%
Grade 1		3	5.0	2	3.8	5	4.5
Grade 2	*	22	36.7	20	38.5	42	37.5
Grade 3		35	58.3	30	57.7	65	58.0
Lymph node -ve		26	43.3	22	42.3	48	42.9
Lymph node 1–3 +ve	*	21	35.0	13	25.0	34	30.4
Lymph node >3 +ve		13	21.7	17	32.7	30	26.8
ER positive		44	73.3	32	61.5	76	67.9
ER negative	*	16	26.7	20	38.5	36	32.1
PR positive		20	33.3	18	34.6	38	33.9
PR negative	*	22	36.7	16	30.8	38	33.9
HER2 positive		13	21.7	15	28.8	28	25.0
HER2 negative	*	37	61.7	26	50.0	63	56.3
Vascular Invasion		25	41.7	29	55.8	54	48.2
No vascular invasion		33	55.0	23	44.2	56	50.0
Local recurrence		1	1.7	5	9.6	6	5.4
No local recurrence		59	98.3	47	90.4	106	94.6
Pre-menopausal		14	23.3	15	28.8	29	25.9
Peri-menopausal		15	25.0	11	21.2	26	23.2
Post-menopausal		31	51.7	25	48.1	56	50.0
Blood group A		26	43.3	20	38.5	46	41.1
Blood group B		8	13.3	1	1.9	9	8.0
Blood group AB		6	10.0	4	7.7	10	8.9
Blood group O		20	33.3	27	51.9	47	42.0
Neoadjuvant chemotherapy		3	5.0	9	17.3	12	10.7
No neoadjuvant chemotherapy		57	95.0	43	82.7	100	89.3
Adjuvant Chemotherapy		44	73.3	34	65.4	78	69.6
No adjuvant chemotherapy		16	26.7	18	34.6	34	30.4
Tamoxifen		29	48.3	21	40.4	50	44.6
Arimidex/anastrozole		11	18.3	8	15.4	19	17.0
Herceptin		7	11.7	5	9.6	12	10.7
Other		6	10.1	4	7.6	10	9.0
None		7	11.7	14	26.9	21	18.8
Current smoker		3	5.0	2	3.8	5	4.5
Ex-smoker		20	33.3	14	26.9	34	30.4
Non-smoker		36	60.0	31	59.6	67	59.8
Current drinker		50	83.3	37	71.2	87	77.7
Former drinker		2	3.3	3	5.8	5	4.5
Non-drinker		7	11.7	7	13.5	14	12.5

Abbreviations: BMI=body mass index; CDH5=cadherin-5; ER=oestrogen receptor; HER2=receptor tyrosine-protein kinase erbB-2; HPA=helix pomatia agglutinin; NSR=no sign of recurrence; PR=progesterone receptor; REC=recurrent breast cancer. NSR and REC patients were matched according to asterisked categories. Where percentages do not total 100, the absent data was not collected and/or is unknown.

Back to article page

Table 1 Descriptive covariates, showing clinicopathological, treatment and lifestyle features of patients from which the samples were taken as well as the results that were obtained for biomarker measurement

Search

Quick links